{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:09:11Z","timestamp":1787508551553,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejmech.2020.112811","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T02:59:56Z","timestamp":1599706796000},"page":"112811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility"],"prefix":"10.1016","volume":"206","author":[{"given":"Zhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasulu","family":"Cherukupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112811_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.1206399","article-title":"AIDS. Turning the tide against HIV","volume":"333","author":"Shattock","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112811_bib2","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1073\/pnas.1720975115","article-title":"Future of nonnucleoside reverse transcriptase inhibitors","volume":"115","author":"Sluis-Cremer","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112811_bib4","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1021\/ja4018418","article-title":"Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors","volume":"135","author":"Bec","year":"2013","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112811_bib5","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic,","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Du","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112811_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2336","article-title":"HIV drug development: the next 25 years","volume":"6","author":"Flexner","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112811_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2018.09.013","article-title":"Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"158","author":"Gu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/med.21544","article-title":"Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors","volume":"39","author":"Battini","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112811_bib10","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s40265-018-0993-4","article-title":"Doravirine: first global approval","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112811_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In\u00a0vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112811_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2019.02.007","article-title":"Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors","volume":"53","author":"Sterrantino","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112811_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jac\/dky464","article-title":"Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients","volume":"74","author":"Soulie","year":"2019","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112811_bib14","doi-asserted-by":"crossref","first-page":"E1\u2212E72","DOI":"10.1002\/med.20241","article-title":"HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design","volume":"33","author":"Zhan","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112811_bib15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","article-title":"HIV drug resistance - an emerging threat to epidemic control","volume":"377","author":"Beyrer","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112811_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2020.112811_bib17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.apsb.2015.09.001","article-title":"An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014","volume":"5","author":"De Clercq","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2020.112811_bib18","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 nonnucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib19","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1021\/acs.jmedchem.7b00332","article-title":"Structure-based optimization of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants","volume":"60","author":"Kang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s42004-019-0174-8","article-title":"Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"2","author":"Kang","year":"2019","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.apsb.2019.08.013","article-title":"Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs","volume":"10","author":"Kang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2020.112811_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jmedchem.9b01769","article-title":"Discovery and characterization of fluorine-substituted diarylpyrimidine derivatives as novel HIV-1 NNRTIs with highly improved resistance profiles and low activity for the hERG ion channel","volume":"63","author":"Kang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib23","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties","volume":"63","author":"Kang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36340","article-title":"Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors","volume":"7","author":"Yang","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2020.112811_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/med.21634","article-title":"Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules","volume":"40","author":"Kourounakis","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112811_bib26","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/med.21581","article-title":"Molecular design opportunities presented by solvent-exposed regions of target proteins","volume":"39","author":"Jiang","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112811_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp3: a new parameter for drug-likeness","author":"Wei","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112811_bib28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.bmc.2016.12.017","article-title":"Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)","volume":"25","author":"Ren","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.apsb.2019.09.007","article-title":"Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2020.112811_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/acsmedchemlett.7b00524","article-title":"Discovery of novel diarylpyrimidine derivatives as potent HIV-1 NNRTIs targeting the \u201cNNRTI Adjacent\u201d binding site","volume":"9","author":"Huo","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112811_bib31","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","volume":"62","author":"Huang","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1021\/tx3004196","article-title":"Central nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and Matrix-assisted laser desorption\/ionization imaging MS investigation into central nervous system toxicity","volume":"26","author":"Castellino","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2020.112811_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bioorg.2017.09.019","article-title":"Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines","volume":"75","author":"Basiri","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib34","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/cbdd.13373","article-title":"Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors","volume":"92","author":"Wang","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112811_bib35","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1021\/acs.jmedchem.8b01656","article-title":"Identification of dihydrofuro[3,4-d]pyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties","volume":"62","author":"Kang","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112811_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1359-6446(99)01451-8","article-title":"Computational methods for the prediction of \u2018drug-likeness\u2019","volume":"5","author":"Clark","year":"2000","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112811_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1023\/A:1012188625088","article-title":"Polar molecular surface properties predict the intestinal absorption of drugs in humans","volume":"14","author":"Palm","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2020.112811_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40262-019-00830-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine: an updated review","volume":"59","author":"Havens","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2020.112811_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13321-018-0283-x","article-title":"ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database","volume":"10","author":"Dong","year":"2018","journal-title":"J.\u00a0Cheminf."},{"key":"10.1016\/j.ejmech.2020.112811_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","article-title":"Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds","volume":"20","author":"Pauwels","year":"1988","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ejmech.2020.112811_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2020.112811_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0166-0934(93)90054-U","article-title":"Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase","volume":"44","author":"Suzuki","year":"1993","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ejmech.2020.112811_bib43","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1039\/C9OB00032A","article-title":"Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus","volume":"17","author":"Zhou","year":"2019","journal-title":"Org. Biomol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420307832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420307832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:18:11Z","timestamp":1759328291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420307832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":43,"alternative-id":["S0223523420307832"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112811","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112811"}}